Hanlin Gao Sells 1,075 Shares of Fulgent Genetics (NASDAQ:FLGT) Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) insider Hanlin Gao sold 1,075 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $28.33, for a total transaction of $30,454.75. Following the completion of the transaction, the insider owned 952,890 shares in the company, valued at approximately $26,995,373.70. This trade represents a 0.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Hanlin Gao also recently made the following trade(s):

• On Friday, November 28th, Hanlin Gao sold 943 shares of Fulgent Genetics stock. The stock was sold at an average price of $29.57, for a total value of $27,884.51.
• On Monday, November 24th, Hanlin Gao sold 535 shares of Fulgent Genetics stock. The stock was sold at an average price of $30.47, for a total value of $16,301.45.

Fulgent Genetics Stock Performance

Shares of Fulgent Genetics stock opened at $28.30 on Friday. Fulgent Genetics, Inc. has a 52-week low of $14.57 and a 52-week high of $31.04. The business’s 50 day simple moving average is $25.36 and its 200 day simple moving average is $22.21. The firm has a market cap of $874.75 million, a PE ratio of -20.36 and a beta of 0.65.

Fulgent Genetics (NASDAQ:FLGT) last issued its earnings results on Friday, November 7th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of ($0.22) by $0.36. Fulgent Genetics had a negative return on equity of 2.55% and a negative net margin of 13.62%.The company had revenue of $84.07 million during the quarter, compared to the consensus estimate of $81.43 million. Fulgent Genetics has set its FY 2025 guidance at 0.300-0.300 EPS. As a group, equities research analysts predict that Fulgent Genetics, Inc. will post -0.85 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Raymond James Financial reaffirmed an “outperform” rating and set a $36.00 target price on shares of Fulgent Genetics in a research report on Friday, November 14th. Wall Street Zen raised Fulgent Genetics from a “hold” rating to a “buy” rating in a report on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Fulgent Genetics in a research note on Wednesday, October 8th. Finally, Piper Sandler lifted their target price on Fulgent Genetics from $21.00 to $30.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $32.00.

Hedge Funds Weigh In On Fulgent Genetics

A number of hedge funds have recently bought and sold shares of the business. Qube Research & Technologies Ltd grew its holdings in Fulgent Genetics by 52.4% during the third quarter. Qube Research & Technologies Ltd now owns 85,059 shares of the company’s stock valued at $1,922,000 after purchasing an additional 29,264 shares during the period. Millennium Management LLC boosted its holdings in shares of Fulgent Genetics by 1.8% in the 3rd quarter. Millennium Management LLC now owns 1,468,844 shares of the company’s stock worth $33,196,000 after purchasing an additional 26,582 shares during the period. Brevan Howard Capital Management LP purchased a new position in shares of Fulgent Genetics during the third quarter valued at approximately $509,000. Bank of America Corp DE grew its holdings in shares of Fulgent Genetics by 67.1% in the third quarter. Bank of America Corp DE now owns 156,251 shares of the company’s stock worth $3,531,000 after purchasing an additional 62,726 shares during the last quarter. Finally, Boothbay Fund Management LLC bought a new position in Fulgent Genetics in the third quarter worth approximately $437,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.